Expanded the indication from adults to pediatric patients 12 - < 18 years of age, weighing at least 35kSafety and efficacy in pediatric patients with chronic hepatitis B < 12 years old or weighing < 35 kg have not been established In a clinical trial in pediatric patients 12 - <18 years, the mean rate of bone mineral density gain was less in Viread-treated patients compared to placeboInformation on dosing, adverse reactions, and clinical trial Postmarketing study
|